See Recent Shionogi-Sponsored Congress Presentations
Congresses
As part of our commitment to addressing unmet medical needs, Shionogi continues to investigate approved products and pipeline compounds. Shionogi presents its research at major congress events globally.
The content contained herein is for your information only. No reproduction, alteration, or distribution of this information is permitted. Information about investigational compounds or investigational uses of products does not imply FDA approval of these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the investigational compounds or investigational uses will receive FDA approval. Shionogi does not recommend or suggest use of its products in a manner inconsistent with FDA-approved labeling.
Select a congress event or filter to view available congress presentations.
You Are Viewing Presentations
Safety, tolerability, and pharmacokinetics of secutrelvir: single and multiple oral doses, and drug-drug interaction with midazolam
Safety, tolerability, and pharmacokinetics of secutrelvir: single and multiple oral doses, and drug-drug interaction with midazolam
Smartphone application-mediated, supervised, at-home telespirometry identifies statistically significant differences in erect and supine slow vital capacity and ALSFRS-R decline as a function of non-invasive ventilation treatment status in multicenter, prospective, longitudinal, observational clinical study [NCT05106569]
Smartphone application-mediated, supervised, at-home telespirometry identifies statistically significant differences in erect and supine slow vital capacity and ALSFRS-R decline as a function of non-invasive ventilation treatment status in multicenter, prospective, longitudinal, observational clinical study [NCT05106569]
The impact of xeruborbactam on in vitro activity of cefiderocol against a challenge panel of Acinetobacter baumannii enriched in isolates with increased cefiderocol MICs
The impact of xeruborbactam on in vitro activity of cefiderocol against a challenge panel of Acinetobacter baumannii enriched in isolates with increased cefiderocol MICs
The impact of xeruborbactam on in vitro activity of cefiderocol against a challenge panel of Enterobacterales enriched with isolates with increased cefiderocol MICs
The impact of xeruborbactam on in vitro activity of cefiderocol against a challenge panel of Enterobacterales enriched with isolates with increased cefiderocol MICs
The time to return to work in healthcare workers with COVID-19 infection treated with ensitrelvir, a novel oral inhibitor of 3C-like protease of SARS-CoV-2
The time to return to work in healthcare workers with COVID-19 infection treated with ensitrelvir, a novel oral inhibitor of 3C-like protease of SARS-CoV-2
Therapeutic effect of delayed treatment with a second-generation 3CL protease inhibitor S-892216 in hamsters infected with SARS-CoV-2
Therapeutic effect of delayed treatment with a second-generation 3CL protease inhibitor S-892216 in hamsters infected with SARS-CoV-2
You Are Viewing Congress Locations
ASM Microbe 2026
ESPID 2026
AAN 2026
ESCMID 2026
CROI 2026
GSA 2025
APCCMI 2025
ASCP 2025
NACFC 2025
IDWeek 2025
AVG and IMRP 2025
ASM Microbe 2025
ESCMID 2025
ISIRV 2025
CROI 2025
SCCM 2025
IDWeek 2024
NACFC 2024
